Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
FibroGen, Inc - Common Stock
(NQ:
FGEN
)
9.710
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about FibroGen, Inc - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stocks That Hit 52-Week Lows On Friday
↗
July 21, 2023
On Friday, 54 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
July 20, 2023
During Thursday's session, 40 stocks hit new 52-week lows.
Via
Benzinga
FibroGen Shares Are Tumbling After Another Pamrevlumab Trial Setback
↗
June 26, 2023
FibroGen Inc (NASDAQ: FGEN) shares are trading lower after the company
Via
Benzinga
FibroGen's Return on Invested Capital Overview
↗
May 23, 2023
Via
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
↗
July 18, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
↗
July 01, 2023
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Via
The Motley Fool
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
↗
June 30, 2023
Major indexes rebounded strongly and many stocks flashed buy signals.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2023
↗
June 27, 2023
Via
Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Fibrogen, Inc. and Encourages Investors With Losses to Contact the Firm
June 27, 2023
From
The Schall Law Firm
Via
Business Wire
Dow Surges Over 50 Points; Avalo Therapeutics Shares Plummet
↗
June 26, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining more than 50 points on Monday. The Dow traded up 0.18% to 33,788.05 while the NASDAQ fell 0.61% to 13,410.63. The S&P 500,...
Via
Benzinga
Analyst Downgrades FibroGen On Questions Regarding Future Direction
↗
June 26, 2023
Earlier today, FibroGen Inc (NASDAQ: FGEN) said its Phase 3 ZEPHYRUS-1 trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of change in forced vital capacity...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
June 26, 2023
Via
Benzinga
Stocks Modestly Lower; Dow Looks To Extend Losing Streak
↗
June 26, 2023
Stocks are modestly below breakeven this afternoon.
Via
Talk Markets
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
June 26, 2023
From
The Schall Law Firm
Via
Business Wire
Crude Oil Rises; Carnival Shares Drop After Q2 Results
↗
June 26, 2023
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday. The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also...
Via
Benzinga
Is the Stock Market Closed on the Fourth of July 2023?
↗
June 26, 2023
Investors are looking for information about the stock market being closed on the Fourth of July and we've got the answers they seek!
Via
InvestorPlace
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 26, 2023
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
↗
June 26, 2023
Via
Benzinga
Is the Stock Market Closed on July 3, 2023?
↗
June 26, 2023
Investors are preparing for Independence Day and that has some traders wondering if the stock market is closed on July 3, 2023.
Via
InvestorPlace
Insiders Promise Not to Sell AMTD Digital (HKD) Stock Until 2025
↗
June 26, 2023
AMTD Digital (HKD) stock is on the move Monday after insiders promised not to sell shares on the public market for a few more years.
Via
InvestorPlace
Why Is FibroGen (FGEN) Stock Down 81% Today?
↗
June 26, 2023
FibroGen (FGEN) stock is heading lower on Monday after the company's Phase 3 clinical trial failed to meet its primary endpoint.
Via
InvestorPlace
FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug
↗
June 26, 2023
This is the company's second high-profile failure this month.
Via
Investor's Business Daily
US Stocks Edge Higher; Goldman Sachs Downgrades Tesla To Neutral
↗
June 26, 2023
U.S. stocks traded slightly higher this morning, with the Dow Jones gaining around 25 points on Monday. Following the market opening Monday, the Dow traded up 0.08% to 33,753.64 while the NASDAQ rose...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
June 26, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
June 09, 2023
Via
Benzinga
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
June 07, 2023
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for...
Via
Benzinga
FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost
↗
June 07, 2023
The company's lead drug didn't improve upper-limb mobility for some patients with the disease.
Via
Investor's Business Daily
FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal
↗
June 07, 2023
FibroGen Inc (NASDAQ: FGEN) announced topline data from the Phase 3 LELANTOS-1 trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD)
Via
Benzinga
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
↗
June 06, 2023
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
↗
June 02, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
